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Abstract 
Background: Intermittent preventive treatment of malaria in pregnancy with 3+ doses of sulfadoxine‑pyrimeth‑
amine (IPTp‑SP) reduces maternal mortality and stillbirths in malaria endemic areas. Between December 2014 and 
December 2015, a project to scale up IPTp‑SP to all pregnant women was implemented in three local government 
areas (LGA) of Sokoto State, Nigeria. The intervention included community education and mobilization, household 
distribution of SP, and community health information systems that reminded mothers of upcoming SP doses. Health 
facility IPTp‑SP distribution continued in three intervention (population 661,606) and one counterfactual (population 
167,971) LGAs. During the project lifespan, 31,493 pregnant women were eligible for at least one dose of IPTp‑SP.
Methods: Community and facility data on IPTp‑SP distribution were collected in all four LGAs. Data from a subset 
of 9427 pregnant women, who were followed through 42 days postpartum, were analysed to assess associations 
between SP dosages and newborn status. Nominal cost and expense data in 2015 Nigerian Naira were obtained from 
expenditure records on the distribution of SP.
Results: Eighty‑two percent (n = 25,841) of eligible women received one or more doses of IPTp‑SP. The SP1 coverage 
was 95% in the intervention LGAs; 26% in the counterfactual. Measurable SP3+ coverage was 45% in the interven‑
tion and 0% in the counterfactual LGAs. The mean number of SP doses in the intervention LGAs was 2.1; 0.4 in the 
counterfactual. Increased doses of IPTp‑SP were associated with linear increases in newborn head circumference and 
lower odds of stillbirth. Any antenatal care utilization predicted larger newborn head circumference and lower odds 
of stillbirth. The cost of delivering three doses of SP, inclusive of the cost of medicines, was US$0.93–$1.20.
Conclusions: It is feasible, safe, and affordable to scale up the delivery of high impact IPTp‑SP interventions in low 
resource malaria endemic settings, where few women access facility‑based maternal health services.
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Background
In 2015, there were an estimated 214 million malaria 
cases and 438,000 malaria deaths in the world [1]. Sub-
Saharan Africa accounted for 89% of global malaria cases 
and 91% of malarial deaths [2]. Nigeria alone accounted 
for almost 25% of malarial deaths in Africa [3]. In 2009, 
the Nigeria Federal Ministry of Health estimated that 
malaria was a direct contributor to 11% of overall mater-
nal mortality, 25% of infant mortality and 30% of under-
five mortality [3].
In Nigeria–with its estimated 6.35 million annual 
births in 2015—and in malaria-endemic settings, preg-
nant women, primipara in particular, are vulnerable 
to malarial infection [4–6]. On account of weakened 
immune systems, pregnant women are four times more 
likely than non-pregnant adults to suffer from sympto-
matic forms of malaria [6]. Furthermore, social factors 
such as unequal balance of power between women and 
men, constrain women’s equitable access to financing and 
health. This double burden undermines women’s abil-
ity to respond appropriately, and access prevention and 
treatment for malaria in pregnancy, even when services 
are available [7].
WHO-recommended strategies for the prevention 
and management of malaria during pregnancy comprise 
a three-pronged approach: (1) use of insecticide treated 
nets, (2) intermittent preventive treatment (IPTp), and 
(3) effective case management of malarial illness [8]. This 
approach was nuanced in 2012 with a call for countries 
to scale up IPTp [9]. WHO recommends the use of sul-
fadoxine-pyrimethamine (IPTp-SP), with a prescribed 
minimum of three doses during focused antenatal care 
visits. Each dose of IPTp-SP is expected to be recorded to 
enhance the monitoring of pregnant women that receive 
successive doses (i.e., IPTp-1, IPTp-2, IPTp-3, IPTp-4, 
etc.).
Malaria and fetal growth
Malaria in pregnancy (MiP) has been shown to have an 
impact on fetal growth and birth outcomes [6, 10, 11]. 
Small size at birth has implications for newborn sur-
vival and long-term implications for a child’s growth 
and development [19]. Most studies on the impact of 
placental malaria on fetal growth have relied on birth-
weight as the outcome. In resource poor settings where 
many women give birth at home, mechanisms are scarce 
to weigh newborns [12–15], Sreeramareddy et  al. have 
argued that in contexts where home births are prevalent, 
surrogate measurement approaches that do not require a 
weighing scale to determine low birth weight, are recom-
mended for implementation [12].
Malaria and stillbirths
There were an estimated 2.6 million (2.4–3.0 million) 
stillborn babies in the world in 2015 [16]. Ninety-eight 
percent of stillbirths occurred in low and middle income 
countries; Africa and Asia accounted for 77% of the 
global stillbirth burden [16]. With an estimated 40.1 still-
births per 1000 live births, Nigeria has the second high-
est number of stillbirths in the world [17]. Nonetheless, 
the true magnitude of stillbirths in Nigeria is difficult to 
estimate in the absence of standardized national policies 
or protocols that enjoin facilities and communities to 
record, audit or to review causes of stillbirth [18].
Van Geertruyden et  al. in a systematic review of 117 
malarial studies conducted between 1948 and 2002 found 
that placental malaria was significantly associated with an 
increased odds of stillbirth (OR 2.19; 95% CI 1.49–3.22) 
[19]. However, Radeva-Petrova et  al. noted that there 
were too few publications that studied a direct associa-
tion between IPTp-SP and stillbirths [20]. The authors 
concluded that published studies were too “underpow-
ered to collect clinically important differences” [20].
IPTp‑SP and ITNs for the prevention of malaria 
in pregnancy in Nigeria
Nigeria adopted the IPTp-SP strategy in 2005 [21]. SP 
was included in the national essential list of medicines 
as an over-the-counter medicine in 2005 [22]. Nigeria’s 
efforts to deliver IPTp-SP services during ANC care have 
not been successful or impactful [23]. In 2013, only 23% 
of women who had given birth in the two years preced-
ing a survey received any dose of IPTp-SP when pregnant 
[24]. About 15% had received two doses of and just 6% 
received three doses of SP (SP3) [24]. In effect, the major-
ity of pregnant women and their unborn babies in Nige-
ria are not adequately protected from placental malaria 
and its consequences [25].
A concern expressed in a 2013 WHO Consensus State-
ment on MiP, equally applicable to Nigeria, was that 
“despite clear global gains in malaria control, the deliv-
ery of MiP interventions remains suboptimal in most 
endemic countries” [9]. Too many women that attended 
antenatal care did not receive at least two doses of SP 
before delivery. There is now an urgent global call for 
new approaches and interventions to reduce missed 
opportunities and, in particular, to substantially increase 
the coverage of SP among pregnant women [9]. In 2013, 
the WHO Policy Brief for the implementation of IPTp 
called for research on “innovative strategies to improve 
the delivery of IPTp-SP and malaria case management 
among pregnant women at the primary health centre 
level”, and for “innovative community strategies that do 
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not detract from ANC services to increase IPTp coverage 
(such as community-based ANC outreach, promotion or 
distribution of IPTp)” [26]. The policy brief also called for 
research into “methods for using health system informa-
tion systems for routine monitoring of IPTp-SP implemen-
tation and effectiveness” [26].
A recent study in Southeastern Nigeria that utilized 
community-based workers to successfully distribute IPT-
SP in community settings, reported that women in inter-
vention areas were significantly more likely to ingest at 
least two doses of IPTp-SP [27]. However, the study did 
not test for the scalability of community-based distribu-
tion, nor did it track for associated newborn outcomes.
The Sokoto State malaria in pregnancy project (MIPP)
MiPP was a yearlong project funded by Bill and Melinda 
Gates Foundation and implemented by JSI Research & 
Training Institute, Inc. that ended in December 2015. The 
project was undertaken in three local government areas 
(LGAs) of Sokoto state, Nigeria. The default IPTp-SP 
programme was a facility-only activity operated as part 
of its focused antenatal care services based on national 
guidelines [21]. The MiPP programme, to the best of our 
knowledge, is the first project in Nigeria and elsewhere, 
to include community-based delivery approaches and to 
track at scale, the number of IPTp-SP doses ingested by 
pregnant women, and associated newborn outcomes.
Sokoto State
Sokoto State is located in the North West Zone of Nigeria 
between longitude 11′′ 30–13′′ 50 and latitude 4′′–6′′. It 
borders Niger Republic to the north and Benin Republic 
to the northwest, Kebbi State to south and Zamfara State 
to the east. It has a land mass area of about 32,000 sq km, 
and consists of 23 local government areas and 244 politi-
cal wards. Ward Development Committees (WDCs) are 
the smallest unit of governance which typically manage 
a revolving drug fund, supervise a cadre of community-
based health volunteers (CBHVs), and oversee primary 
health facilities in their jurisdiction [28]. The popula-
tion is predominantly rural, Muslim and consists almost 
entirely of Hausa/Fulani ethnic groups.
Sulfadoxine‑pyrimethamine and insecticide‑treated net use 
profile in Sokoto State
Malaria is seasonal in Sokoto State, with peak trans-
mission from May to December. The highest point 
prevalence of parasitaemia—which mirrors rainfall pat-
terns—is in August (59.5%), and the lowest is in March 
(9.18%) [29]. In 2013, the state prevalence rate of MiP 
was 9% and it ranged from 35% in the highest burden 
LGA to 1% in the lowest burden [30]. In 2013, 80% of 
women in the state did not use antenatal care in their 
last pregnancy—the largest non-use of ANC services 
by a state in Nigeria [24]. Of the 17.4% of women that 
obtained ANC from a skilled attendant, three in five 
received no SP whatsoever [24]. Less than 5% and less 
than 1% of all pregnant women in the state received SP2 
and SP3 respectively in 2013 [24].
Study overview
The study objectives were to:
1. Examine scale-up mechanisms that enable increased 
SP coverage through community-based primary 
health care delivery, without reducing facility uptake 
of SP.
2. Examine community acceptance of SP and the likeli-
hood of long-term community-sustained demand.
3. Document associations, if any, between increased 
SP3 coverage and improved intrauterine conditions 
for newborn, as measured by head circumference 
increments and declines in still birth rates.
4. Estimate the costs of delivering SP at scale per 
woman for a three doses or higher regimen.
The MiPP intervention
The intervention consisted of house-to-house distribu-
tion of SP to eligible pregnant women—administered 
through directly observed treatment (DOTs)—by trained 
community-based health volunteers (CBHVs). Commu-
nity distribution of SP was limited to the first three doses 
of SP; SP4 and higher doses were intentionally designated 
for administration in a health facility, to promote the use 
of facilities. The MiPP intervention was twinned with 
an ongoing facility-based SP distribution as well as case 
management of suspected cases of malaria in health cent-
ers in intervention and counterfactual LGAs. Similarly, 
established and ongoing LLIN distribution continued in 
health facilities in both intervention and counterfactual 
LGAs.
Outcomes tracked
The programme tracked three principal outcomes. The 
first was the percentage IPTp-SP coverage among all 
pregnant women between April and November 2015 and 
by number of SP doses ingested. Head circumferences of 
live newborns was tracked, as a measure of intrauterine 
growth function. Head circumference was measured in 
centimetres, to the 10th of a centimetre, using a stand-
ardized protocol. A tape measure was placed above the 
ears and midway between eyebrows and the hairline to 
the occipital prominence at the back of the head. CBHV 
supervisors, all of whom were literate and numerate, car-
ried out the measurements. Newborn head circumfer-
ence, as a measure of intrauterine growth was tracked 
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instead birthweight because it was considered less sus-
ceptible to the obesogenic effects of pregnancy [31]. 
Newborn head circumference has also been shown to be 
inversely related to and sensitive to malaria-associated 
lesions of the placenta [13, 31, 32]. Finally, in the context 
of Sokoto State, the measurement of head circumference 
was less intrusive and more readily managed by commu-
nity health workers with adequate training.
Head circumference measurements were limited to live 
newborns whose mothers resided in one of four project 
LGAs, that were delivered—home or facility births—
during the intervention period. Head circumference 
measurements were not undertaken in newborns whose 
mothers (a) recently migrated into the intervention area 
and had not been exposed to the intervention (b) older 
than seven days postpartum at the time of measurement, 
and (c) stillborn babies. Head circumference measure-
ments were limited to those obtained within seven days 
postpartum to reduce temporal biases in our head cir-
cumference measurements. It was not culturally per-
missive to measure the head circumference of stillborn 
babies.
The third outcome was the incidence of stillbirths. 
Stillbirths were defined as deliveries that occurred after 
7 months of gestation in which a baby was birthed with-
out any signs of life (no breathing, no movement, and no 
sound) as reported by the mother or an informed family 
member.
Intervention LGAs and the counterfactual LGA selection
Dange Shuni Goronyo and Silame (combined 2015 
population, according to official Sokoto State esti-
mates  =  661,606) LGAs were purposively selected as 
intervention LGAs, and Yabo LGA, the fourth (2015 
population, according to official Sokoto State esti-
mates  =  167,971), was selected as the counterfactual 
LGA. The selection criteria were that all LGAs had a high 
prevalence of malaria in pregnancy and that at one LGA 
each in the intervention group, was selected from each 
of the State’s three senatorial zones. Such political bal-
ance was considered important for the potential future 
adoption of study recommendations across Sokoto state. 
Figure 1 shows a mapping of the intervention and coun-
terfactual LGAs.
Mapping households and identifying pregnant women in the 
community
In the three intervention LGAs, households were mapped 
and all women of reproductive age (WRA) were enumer-
ated and registered in a household registration system 
(HRS) database. Designed with a household as the unit 
of analysis, the database contained compound numbers, 
household numbers, the number of WRA, pregnant 
women, and children under five. It also identified each 
woman—at the time of mapping exercise—that was preg-
nant, that was eligible for SP, when she got what SP dose, 
and where she resided. Any changes in these parameters 
in a given household were recorded into the Household 
Register Book (HRB), which was used to update the HRS 
on a monthly basis. Households were not mapped in the 
counterfactual LGA. Instead, official census projections 
were used to estimate the expected number of eligible 
pregnant women during the study period.
Implementing the malaria in pregnancy project
The IPTp-SP distribution built upon an existing com-
munity based distribution system introduced in 2013 by 
Sokoto State government with technical support from 
JSI/USAID. The community-based health volunteer sys-
tem is comprised of 10 CBHVs per ward, which formed 
a cadre of 2440 CBHVs throughout the 244 wards in the 
State. CBHVs had already been trained to deliver the key 
counseling messages prescribed by the WHO and Nige-
ria’s National Primary Health Care Development Agency, 
and were assigned the additional task of delivering SP to 
women at home. CBHVs already had a system in place to 
implement an on-demand distribution of chlorhexidine 
gel 7.1% digluconate and misoprostol tablets to women 
that delivered their babies in home settings, which is 
shown in Fig. 2 [24, 33]. The study added five additional 
CBHV per ward to increase the geographic coverage of 
the intervention LGAs. With these additions, the number 
of CBHVs per 10,000 residents in the intervention LGAs 
of Silame, Dange Shuni and Goronyo were 10, 7 and 6, 
respectively. It was 7 per 10,000 in Yabo, the counterfac-
tual LGA.
The medicine delivery component of the CBHV sys-
tem had an inbuilt data collection system managed by a 
community drug keeper (CDK) and a supervising facil-
ity-based health worker to monitor distribution at the 
community level. Data captured in the outcome form 
included the condition of the newborn and mother at 
birth, of the newborn at birth—stillbirth or live birth—
at days 7, 14 and 28 postpartum. The study team modi-
fied the outcome form to capture the number of SP doses 
a woman received in the intervention LGAs and data 
collection was managed by CBHV supervisors. In the 
counterfactual LGA, the outcome form was revised to 
exclude intervention-related questions that did not apply. 
It nonetheless inquired a pregnant woman’s primipara 
status, ANC status, SP doses taken, gestation at time of 
delivery, the state of newborns, and head circumference 
measurements. In the place of CBHV supervisors in the 
counterfactual LGA, 10 data collectors were recruited. 
These data collectors were titled as “home visitors” as 
they had no role in CBHV supervision. See Additional 
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file 1 for examples of the modified outcome forms, for the 
intervention and counterfactual LGAs.
SP commodity logistics
In every ward in the intervention LGAs, one designated 
health facility served as a supply hub for SP intended 
for community distribution. The health facilities were 
selected based on their central proximity in a ward, pos-
sessing a good volume of clients, the availability of skilled 
service providers, and satisfactory medicines storage 
capacity. These health facilities were part of a long estab-
lished statewide supply grid for malaria commodities 
including artemisinin-based combination therapy (ACT) 
medicines, rapid diagnostic testing kits (RDT), (LLIN) 
and SP. These commodities were provided by US Presi-
dential Malaria Initiative (PMI) through the USAID/JSI 
DELIVER Project. Health facilities in the counterfactual 
LGAs were similarly supplied with identical malaria com-
modities. Two service providers from each designated 
health facility were co-trained with CBHV supervisors 
on the community distribution process and on the Nige-
ria National Malaria policy guidelines—on SP dosing, 
malaria case management—referrals and documentation 
of services rendered into registers and commodity stock 
books. Health facilities supplied SP tablets to CHBV 
supervisors who in turn distributed them to the CBHVs in 
the wards. Within each ward, a CBHV regularly covered a 
defined catchment of compounds/households.
Fig. 1 Map of intervention and counterfactual LGAs
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SP distribution process
The scale-up of community distribution of SP was tri-
aled in three wards (one ward per LGA) for 1  week, 
and reached all known pregnant women eligible for SP 
(n =  264). During the trial, it was learned that the sys-
tem used to identify households caused avoidable delays 
in tracking women. It did not work for the CBHVs, most 
of whom were unable to read or write. It was successfully 
replaced at scale up by the use of simple pictograms that 
uniquely identified households. Additional file 2 provides 
a sample of the pictograms used by the CBHV’s. CBHVs 
and their supervisors met weekly, and updated their lists 
of eligible pregnant women for IPTp–SP, and made quan-
tifications of SP doses needed.
At the household level, CBHVs counselled pregnant 
women and inquired about any symptoms of malaria, 
the gestational age of pregnancy and presence of quick-
ening, history of SP administration within last 4 weeks, a 
history of reaction to sulphur-containing drugs. CBHVs 
counseled women on the benefits of IPTp-SP, of LLIN 
utilization, good nutrition and the importance of ANC 
visits. Eligible and healthy pregnant women were given a 
dose of SP administered via DOTs and told the date of 
their next monthly dose. CBHVs issued a colour-coded 
card linked to a specific dosage administered—white for 
1st dose, yellow for 2nd dose and green for the 3rd dose. 
Each SP card was pre-recorded with a given woman’s 
compound number, household number and her unique 
number. Mothers were advised to bring their SP cards to 
ANC clinic visits. This setup enabled more reliable data 
exchange with health workers in health facilities on what 
doses a woman had received at home. Examples of the 
cards used to track SP doses can be found in Additional 
file 3. Figure 3 shows the decision tree for IPTp-SP dosage 
and referral protocol applied in the MiPP project.
Review meetings
Two sets of review meetings—a monthly one with 
CBHVs and their supervisors and a bi-monthly one with 
LGA officers—were regularly conducted. At monthly 
ward meetings, CBHVs with their supervisors, service 
providers and WDC members, LGA RBM officer, LGA 
M&E officer and project team members reviewed the 
month’s work and exchanged experiences. Three wards 
were clustered per meeting for cross-learning. One out-
come of such meetings, at the behest of community lead-
ers, was the introduction of outreach ANC services to 
underserved hard-to-reach areas. ANC clinics run by 
community health extension workers and midwives were 
held at least thrice there so that three doses of SP were 
delivered.
At LGA bi-monthly review meetings, feedback was 
provided to LGA level stakeholders, and lessons for 
future use beyond the project, were drawn. Participants 
at these meetings included the LGA chairman or his des-
ignate, the LGA primary health care director and team 
(the MCH coordinator, RBM officer and M&E officer), 
district heads from the LGA, WDC representatives, 
Sokoto State Ministry of 
Local Government (MOLG) 
Local Government Areas 
(LGA) (n=23) 
Ward Development 
Commiee (WDC) (n=244) 
Community Drug Keeper 
(CDK) (n=1,220) 
Community Based Health 
Volunteer (CBHV) 
(n=2,440) 
Women in the Community 
1) JSI/USAID works with MOLG, LGA and WDCs to 
advocate for improved MNCH outcomes 
1) Advocacy efforts to reduce aboron sgma 
associated with misoprostol 
2) MOLG procures and distributes misoprostol  and CHX 
to the  WDC 
3) WDC distributes misoprostol and CHX to the CDK 
4) WDC idenfies CDKs 
5) JSI/USAID, LGA and WDC leadership idenfy CBHVs 
6) JSI/USAID trains CDKs and CBHVs 
7) WDC distributes misoprostol  and CHX to the CDK 
8) CDK distributes misoprostol and CHX  to the CBHV 
and monitors stock levels 
1) CDK reports stock levels to the WDC 
2) WDC procures needed stock from MLOG 
9) CBHV monitors the community, idenfies pregnant 
women, and distributes misoprostol  and CHX at the 
community level 
10) CBHV verbally  reports births and outcomes the CDK  
11) CDK records outcomes 
1) CDK  shares data collected with TSHIP at 













Fig. 2 Sokoto State chlorhexidine–misoprostol distribution system
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representatives of the State Primary Health Care Devel-
opment Authority, representatives of the Ministry of 
Local Government, representatives of facility-based ser-
vice providers, three representative CBHV supervisors 
and the project staff. Figure 4 shows the planning schema 
and participants for the MiPP review meetings.
Monitoring the safety of IPTp‑SP delivery
During the project, all service providers searched proac-
tively for reports of adverse reactions to SP use in preg-
nant women. All CBHVs and their supervisors were 
trained on how to ask about any adverse reactions and 
how to document them if they occured. The imperative 
that there be a clear cut history of quickening as a prereq-
uisite for SP use in pregnant women, was reinforced in 
trainings and throughout all review meetings and super-
vision encounters at ward, facility and LGA levels. WDC 
members were also asked to report any suspected adverse 
reactions to SP in their communities. At the health facil-
ity where such practices were the norm, service provid-
ers regularly checked for suspected reactions for onward 
referral to a secondary referral health facility. As found in 
other studies, IPTp-SP was well tolerated; there were no 
reported cases of severe adverse reaction to SP [34].
Ensuring data quality on SP consumption and reporting 
at facility and community levels
Data quality checks of SP doses administered were per-
formed on health facilities’ and CBHV Supervisors’ 
records. At the facility level, daily SP services are typi-
cally summarized into a monthly summary form (MSF), 
which is entered into a cloud-based national DHIS2 data-
base that constitutes Nigeria’s national monthly summary 
health indicators reporting system. The MSF was used as 
the standard with which to measure accuracy. Within the 
DHIS2, each facility that reports data is named and so it 
is possible to compare a facility’s DHIS2 data with what 
was reported in the same facility’s MSF. Between June 
and November, monthly reviews of the DHIS2 reported 
data in a given facility was cross-checked with the MSF. 
Inconsistencies were compiled and shared with a team 
of the LGA Monitoring and Evaluation Officer (LGA 
M&E Officer), the LGA Roll Back Malaria Officer (LGA 
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Fig. 3 Decision tree for SP dosage and referral
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resolution. For example, the problem of non-reporting 
by some facilities was traced to insufficient coordination 
between the LGA RBM Officer and M&E Officers and 
to lack of transportation to reach out to distally located 
facilities. Health facilities in the intervention LGAs added 
up SP doses served in their catchment communities to 
the facility data.
In the intervention LGAs, the HRB master list, an 
aggregation of individual household HRB, contained the 
most up-to-date information of WRA, pregnant women 
and SP doses given. HRB was the source of information 
for CBHVs and their supervisors to prepare and regularly 
update lists of eligible women. CBHVs and their supervi-
sors documented their list of women reached with SP in 
the HRB with which dose and when. CBHV Supervisors 
prepared monthly summary forms from these activities. 
The HRB master list was compared each month with the 
CBHV Supervisors’ monthly summary form. Discrepan-
cies were addressed by CBHV supervisors at follow up 
home visits.
Tracking birth reporting, birth outcomes and head 
circumference measurements
Twelve teams of four data quality auditors, independent 
of other project staff, were recruited to track data quality. 
Each team comprised of three females and one supervi-
sor. Over the life of the project, the teams visited all the 
women recorded with at least one birth—that occurred 
during the project—in the 42 wards of the three inter-
vention and one counterfactual LGAs. Information on 
omitted mothers and births was sought for and collected. 
Mothers—or an informed family member in the event 
of a maternal death—if a CBHV and CBHV Supervisor 
visited, the status of newborns, alive or stillborn, and if 
head circumference was measured within seven days 
among live births. With mothers’ responses as the gold 
standard, births, status of births, and confirmed HC 
measurements were verified. Overall, a 3.7% error rate 
was found with facility-based SP records, 2.5% error 
rate with community-based SP records. There was a 17% 
underreporting of live births and 2.1% error rate with the 
FIGRURE 4: SCHEMA FOR MALARIA IN PREGNANCY REVIEW MEETINGS 
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Feedback  
Types of data collected and reviewed: 
• SP consumpon at community and HF 
• LLIN distributed 
• LLIN & SP stock on hand 
• New pregnant women  
• Pregnancy outcome STATE 
Parcipants: 
WDC chairmen or rep, CBHV Sups,  
CBHVs, Service Providers
Objecves 
• To give feedback to LGA management team for decision making 
• To solicit for needed support to improve project performance 
Parcipants common to both 
meengs: 
LGA RBM, LGA M&E and MiP project 
staff 
Meeng facilitated by Health Facility Service Providers
• Review of previous acon points and level of 
implementaon 
• Data presentaon by CBHVs and CBHV supervisors 
• Data verificaon/reconciliaon by CBHV supervisors, 
service providers & LGA M&E and RBM officers 
Meeng facilitated by LGA RBM Officer 
• Review of last minutes of meeng 
• Presentaon of findings/results, lessons learnt & 
Challenges 
• Discussions 








Fig. 4 Planning schema for MiPP project review meetings
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correct recording of births and outcomes. These were all 
addressed prior to data analysis.
Methods
Data and methodology for the coverage and scale of SP 
doses
From the HRS database, 25,572 women who were eligible 
for SP between April and November in the three inter-
vention LGAs, were identified. Based on actual num-
bers, 94% of pregnant women in the intervention LGAs 
became eligible for SP1 between April and November. In 
the intervention LGAs, the number of pregnant women 
eligible to receive SP1, was used as a denominator to cal-
culate SP1, SP2 and SP3+ coverage (Table 4).
In the counterfactual group, the number of pregnant 
women eligible to receive SP1 over the life of the project 
was estimated. Using the official population estimate for 
Yabo LGA, from the Sokoto State Government (167,971) 
and assuming that 5% of the population was pregnant, 
there were an estimated 8399 pregnant women in Yabo, 
in 2015. Prorating that number for the 8  months of the 
project, there were an estimated 6299 pregnant women in 
Yabo between April and November 2015. Assuming Yabo 
would have the same percentage of women eligible for 
SP1, as found in the intervention areas (94%) it was esti-
mated that there was a total of 5921 women eligible for 
SP1 during the project lifespan (Table 4). This estimate as 
the denominator to calculate SP1 and SP2 coverage.
Univariate and bivariate analyses were performed to 
compare intervention and counterfactual LGAs on the 
number of SP doses and source of SP. Analyses were con-
ducted in Excel spreadsheet®.
Newborn head circumference data and methodology
Programmatic data extracted from outcome forms were 
available for 9241 live births in intervention and coun-
terfactual LGAs between April and November. Head cir-
cumference (analyzed in mm) of live newborns measured 
within 7 days of birth, was available for 6720 (73%) of live 
births. Head circumference data were missing for 2521 
live newborns. Of these, 1721 (19%) mother-newborn 
dyads missed initially, were identified during the data 
quality review in October. For the remaining 800 new-
borns, head circumferences were not measured within 
7 days postpartum.
Independent variables used in this analysis were guided 
by prevailing epidemiological evidence base and by what 
was feasible to collect by CBHV supervisors. These 
included the sex of newborn, gravidity of mothers, suc-
cessive doses of SP, exposure to ANC, month of delivery 
and gestational age at birth. Globally, female newborns 
have smaller head circumferences than male newborns 
[15]. Primigravida women are at higher risk for placental 
malarial infection, [35]. Table  1 presents how each of 
these variables was coded in the analyses.
Univariate analyses tested for any associations between 
a given independent variable and the mean head circum-
ference of live newborns. Unadjusted t tests were used to 
assess any differences within each predictor variable and 
newborn head circumference. Unadjusted tests of cor-
relations between mean head circumference and doses 
of IPTp-SP, and month of birth, were performed. Mean 
newborn head circumferences were used to assess cor-
relations in the number of IPTp-SP doses over the pro-
ject period in the intervention and counterfactual LGAs. 
A multivariate linear regression model was used to test 
for the impact of SP doses and other variables on head 
circumference. Analyses were performed with Excel® and 
SAS v. 9.4.
Stillbirth data and methodology
Data extracted from outcome forms were available for 
9453 term births in both the intervention and control 
LGAs between April and November. To examine the 
impact of IPTp-SP doses on the incidence of stillbirths, 
all confirmed pregnancies that ended in miscarriage 
and abortion, or were delivered before 8 months of ges-
tational age (n = 99) were excluded. If the newborn was 
stillborn, it was coded as “1”; if it was a live birth, it was 
coded as “0.”
Stillbirth rates (SBR), per 1000 births, and correlations 
between SBR and doses of SP were calculated. Unad-
justed and adjusted logistic regression modelling was 
used to predict the odds with 95% confidence intervals, 
of having a stillbirth among women who ingested differ-
ent doses of SP, according to exposure to intervention, 
those who attended at least one ANC visit, gravidity of 
mothers, those who gave birth in a facility vs those who 
gave birth at home, and those who gave birth later (July–
November) vs. those who gave birth earlier (April–June). 
Multivariate logistic regression analysis was used to 
assess whether these associations would hold after con-
trolling for other variables in the model. Analyses were 
conducted in Excel® and SAS v9.4. Table 2 presents each 
variable as coded in the analyses.
Costing data and methodology
Nominal cost and expense data in 2015 Nigerian Naira 
(NGN) directly related to community and facility distri-
bution of SP in the intervention and counterfactual LGAs 
were obtained from project records and other sources. 
The cost estimates obtained are what it would cost the 
state government and LGAs as de jure providers of pri-
mary health care in Nigeria, to deliver SP-related services 
at both the community and facility level, including start-
up costs. Estimates were limited to a 12-month horizon.
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Different degrees of contributions by each service 
component at facility and community levels, towards 
the delivery of SP at facility and community levels, were 
assumed. Table 3 lists the assumptions about the magni-
tude of contributions by each level of care to SP distri-
bution. For this purpose, six cost centers were included 
in the analysis: health facility, LGA technical administra-
tion, CBHV supervisors, WDC, CBHV, and logistics for 
SP distribution. Table 3 provides a summary of each cost 
center, and their relative contribution towards SP distri-
bution the activities involved; these were costed. Twenty-
two work days per month were assumed. Published 
government salary schedules were used to compute 
government officers’ salary costs. Governments officers’ 
salary costs included time spent at monthly LGA level 
review meetings in each LGA attended by representatives 
Table 1 Variables used to understand the impact of SP interventions on head circumference among 6720 live newborns, 
born between May and November 2015
Variable name Definition
Head_circum Head circumference, at birth, in mm n = 6720
Continuous
Girl 1 = Female n = 6712
0 = Male
SPFREQ 0,1,2, 3 + doses of SP n = 6720
Intervention 1 = DANGE SHUNI, Goronyo or Silame LGA, where com‑
munity based SP distribution occurred
n = 6720
0 = Yabo, where no community based SP distribution 
occurred
Primi 1 = Primigravida n = 6711
0 = Multigravida
Month of birth April–November 2015 In the unadjusted analyses, all earlier months are 
compared to November. In the adjusted analyses, 
this variable was used as a continuous variable
n = 6720
Gestational age at birth (months) 2 = 10 n = 6719
1 = 9
0 = 8
Table 2 Variables used to  understand the associations between  SP interventions and  stillbirths between  April 
and November 2015 (n = 9453)
Variable Name Definition N and notes
Stillbirth 1 = Stillbirth A stillbirth was defined as an infant born at least 8 months or 
more of estimated gestational age, who showed no signs of 
life at birth
0 = Live birth Births that occurred before 8 months gestation were coded as 
missing (miscarriage/abortion)
SPFREQ 0,1,2, 3+ doses of SP
Intervention 1 = DANGE SHUNI, Goronyo or Silame LGA, where community 
based SP distribution occurred
0 = Yabo
Any ANC 1 = Yes
0 = No
Primi 1 = Primigravida n = 9438
2 = Multi
Place of delivery 1 = Health facility (hospital, health center/post)
0 = Home
Month of birth 1 = July–November Month of birth
0 = May, June
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of wards. At the community level, costs were attrib-
uted to WDCs and to CBHVs. There was a WDC and 
one CBHV supervisor in each ward. WDCs supported 
CBHVs in the distribution of SP and supervised CBHV, 
as well as ad hoc community meetings that were called to 
tackle issues that could undermine the demand or sup-
ply sides of the programme. CBHV-related costs also 
included level of effort, transportation for SP distribu-
tion and monthly rentals of meeting rooms for ward-level 
CBHV review meetings also attended by LGA officials. 
Costs associated with the transportation and distribution 
of SP to 42 health facilities were captured in central stor-
age costs.
Two ratios were calculated: cost per dose and cost per 
woman served, disaggregated by number of SP doses in 
the intervention and counterfactual group. Ratios were 
obtained from annualized costs derived in each LGA, 
intervention and counterfactual, the total as well as the 
disaggregated number of SP doses distributed, and from 
the total number of women served.
Results
Findings related to coverage and scale‑up of SP use
A combined total of 60,428 compounds which com-
prised 92,240 households with a combined population of 
524,580 residents were mapped and enumerated in the 
three intervention LGAs and registered into the data-
base. According to Sokoto State official figures, there was 
an estimated population of 167,971 in the counterfac-
tual LGA (Table 4). A total of 114,842 women of repro-
ductive age were registered in the intervention LGAs. 
Throughout the intervention period, April-November, a 
total of 25,572 pregnant women in the intervention LGAs 
and an estimated 5921 in the counterfactual LGA were 
eligible to receive SP1 (Table 5). 
Table 5 shows that between April and November 2015, 
the percent of eligible women that got SP1 averaged 95% 
in the intervention LGAs—ranging from 81% in Dange 
Shuni to 100 and 108% respectively in Goronyo and Sil-
ame—compared to 26% in the counterfactual (Figure 5). 
The high SP1 coverage in Goronyo LGA was also influ-
enced by a test conditional cash transfer programme to 
encourage women to attend ANC clinics—including 
those from neighboring LGAs—that was also in effect 
during the study. In Silame LGA, there were a number 
of households whose pregnant women were served with 
SP and not captured in the HRB due to delays in enu-
meration. Consequently, these were not included in the 
denominator, and quite likely yielded an overestimated 
SP1 coverage.
Table 5 shows that the SP2 coverage in the intervention 
LGAs was 68%—and it ranged from 58% in Dange Shuni 
to 83% in Silame LGAs–compared to 13% in the counter-
factual LGA. The SP3 coverage in the intervention group 
was 45%–it ranged from 32% in Dange Shuni to 56% in 
Silame—compared to zero percent in the counterfactual. 
Data on SP3 was unavailable for the counterfactual as the 
DHIS2 does not collect data on SP3 doses and higher.
Figure  5 compares SP1 coverage in intervention and 
counterfactual LGAs in 2014 and 2015. The percent of 
women that received SP1 in the intervention did not 
differ from those that did in the counterfactual in the 
Table 3 Cost centers by level of care and magnitude of their component costs associated with SP distribution
Cost center Level Description Components costed (magnitude)
Health facility Health Facility SP distributed through ANC. Hub for community 
distribution and receipt of community con‑
sumption data
Rent and utilities (10%)
M&E documentation tools (10%)




LGA‑wide, all levels Supervision and program oversight including 
quality assurance, data management and 
coordination
Meeting venue (100%)
LOE for nine key personnel at all levels who contribute 
supervisory and oversight roles and collaborate in 
the program (5% time)
CBHV Supervisor Community/
Facility
Technical supervision of CBHV, assuring SP avail‑
ability to CBHV and data‑driven accountability 
to WDC and HF
LOE (50%)
Transport costs of SP from HF‑CBHV (100%)
Monitoring and Supervision (100%)
CBHV Community Oversight and coordination of community‑level 
operations
CBHV LOE (50%)
Transport cost for SP distribution (100%)
Transport costs for home visits (100%)
Ward Development 
Committees
Community Community mobilization and sustaining program 
momentum
Meeting attendance costs for WDC member (30%)
Meeting attendance cost of CBHV supervisor of ward 
(30%)
Supervision and monitoring of CBHV (100%)
Meeting/dialogue (100%)
Meeting venue (100%)
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Table 5 Number and percentage of eligible women who received SP1, SP2 and SP3 by LGA
Dange Shuni Goronyo Silame Intervention 
combined
Yabo Total
Pregnant women eligible for SP between April and November 2015 9136 10,850 5586 25,572 5921 31,493
Number of SPI doses consumed 7408 10,893 6013 24,314 1527 25,841
% Given SP1 81 100 108 95 26 82
Number of SP2 doses consumed 5334 7304 4656 17,294 767 18,061
% Given SP2 58 67 83 68 13 57
Number of SP3+ doses consumed 2922 5381 3128 11,431 0 11,431
% Given SP3+ 32 50 56 45 0 36
Total number of doses SP doses given 15,664 23,578 13,797 53,039 2294 55,333
















Apr- Nov. 2014 April -Nov. 2015





















Average Facility SP 
 Coverage, 2015 
Fig. 6 Percentage coverage of pregnant women who took SP1 in three intervention LGAs and one counterfactual LGA by source April–November 
2015
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12 months that preceded the 8 month (April–November) 
study period, and it averaged 22%.
Figure  6 shows that across the three intervention 
LGAs, between 55 and 71% of all SP1 through SP6 doses 
consumed were obtained from community channels. A 
26 percentile line drawn through the bar graphs of the 
intervention LGAs indicate that relative to the 26% cov-
erage in the counterfactual LGA which was an all-facility 
distribution scheme, there was a proportional increase in 
health facilities as a source of SP consumed in interven-
tion LGAs. The introduction of community SP distribu-
tion may have helped increase SP uptake in facilities in at 
least two intervention LGAs.
The monthly number of women that consumed SP1, 
SP2 and SP3 in the intervention LGAs, and women that 
consumed SP1 and SP2 in the counterfactual LGA were 
plotted (see Fig. 7). There was an early sharp increase in 
SP1 users suggestive of rapid community adoption aided 
an already well-established community distribution net-
work. There was a subsequent marked increase in the 
uptake of SP2 and SP3 suggestive of sustained continu-
ity of use. From June onwards, there was a pattern of 
convergence between SP1 and SP2 consumption, and by 
November, the number of women that got SP2 exceeded 
those that got SP1—another likely indication of success-
ful follow up of pregnant women that held over time. It 
also reflects a persisting capability of women to demand 
SP3, and the supply system to meet such demand. In 
Yabo LGA, the counterfactual, the trend lines of the 
numbers of women that received SP1 and SP2 per month 
were much lower and changed little throughout the study 
period.
Findings related to newborn head circumference
Data on head circumference were significantly more 
likely to be missing in the intervention (missing 
n  =  2512) versus the counterfactual LGAs (missing 
n = 9) (Chi-sq p < 0.0001). These were babies who were 
past 7  days postpartum whose head circumferences 
were not measured, and therefore excluded. There was 
a strong correlation between later birth months and 
increasing number of IPTp-SP doses (r2 =  0.88) in the 
intervention LGAs. This indicates that more women 
proactively enrolled earlier in their pregnancies when 
the community-based distribution of IPTp-SP com-
menced on April 28, 2015. They were also more likely 
to have received all three recommended doses of IPTp-
SP, than those who enrolled when their pregnancy was 
in far advanced stages of gestation. This correlation 
was weak in the counterfactual LGA where there no 
community mobilization effort (r2 = 0.17) (Fig. 8). The 
mean head circumference among all live newborns was 
355  mm (see Table  6). Table  6 shows that babies born 
later in the year had smaller head circumferences than 
those born in April. A month on month decline in mean 
head circumference was observed in both the inter-
vention and counterfactual LGAs between April and 
November. In all but 1  month (October) head circum-
ferences were consistently larger in the intervention 
LGAs (Table 7) (Fig. 9).   
Fig. 7 Monthly number of pregnant women who took SP1, SP2, SP3 in three intervention LGAs and one counterfactual LGA, Sokoto State, April–
November 2015
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Table 8 presents findings from the univariate analyses. 
As expected, female newborns had significantly smaller 
head circumferences than male newborns. There was a 
linear increase in mean head circumference with each 
additional SP dosage (r-sq. = 0.79) (Fig. 10). Larger and 
statistically significant mean head circumferences were 
observed among newborns whose mothers had at least 
one ANC visit, relative to those whose mothers’ had 
none. There was no significant association between being 
primigravid and a smaller head circumference. Newborns 
in the intervention LGAs had significantly larger head 
circumferences compared to those in the counterfactual 
LGA. 
R² = 0.168 








April May June July August September October November
Counterfactual LGA MIPP Intervenon LGAs Linear (Counterfactual LGA) Linear (MIPP Intervenon LGAs)
Fig. 8 Mean doses of SP between April and November 2015 in the MiPP intervention and counterfactual LGAs
Table 6 Mean head circumference by  month of  birth, 
between April and November 2015
Month of birth n Mean SD
April 755 360.50 22.89
May 887 355.49 20.92
June 838 353.06 20.86
July 766 354.53 23.78
August 809 354.31 22.61
September 860 352.98 26.17
October 959 355.63 20.88
November 846 354.83 21.14
Total 6720 355.11 22.52
Table 7 Mean head circumference by month of birth between April and November 2015 in the Intervention and counter-
factual LGAs
Month of birth Intervention LGAs Counterfactual LGA Pr > |t|
n Mean SD n Mean SD
April 567 362.86 23.94 188 353.35 17.61 <0.0001
May 631 356.79 22.20 256 352.30 16.99 0.00
June 485 354.75 22.85 353 350.75 17.52 0.01
July 515 355.28 25.63 251 352.99 19.41 0.21
August 542 356.67 23.42 267 349.53 20.06 <0.0001
September 626 353.73 27.89 234 350.97 20.81 0.17
October 643 354.13 22.04 316 358.69 17.95 0.00
November 574 355.80 21.24 272 352.78 20.80 0.05
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Table 9 presents the adjusted associations between each 
of the predictor variables and live newborn head circum-
ference. On average, female newborns had head circum-
ferences that were 2.33 mm smaller than male newborns. 
Newborns whose mothers had three or more doses of 
IPTp-SP had a significantly larger head circumference 
than newborns whose mothers ingested 0, 1 or 2 doses. 
On average, the newborns of mothers who had attended 
one or more ANC visits had a significantly larger head 
circumference, of 2 mm, than babies whose mothers had 
no ANC visits. Women who resided in the intervention 
LGAs had newborns with significantly larger mean head 
circumference at 2.88 mm than those living in the coun-
terfactual LGA. There was a significant, negative, linear 
trend in head circumference as birth months progressed 
by 0.64 mm/month from April to November. There was 
no significant association between mothers being primi-
gravida and a lower newborn head circumference. New-
borns that were delivered at 8  months of gestation had 
on average a head circumference 17.83 mm smaller than 
those who delivered at 10 months of gestation.
To test for collinearity between ANC attendance, ges-
tational age and SP dosages two interaction terms were 
constructed. These interaction terms were used to test for 
any distinct impact of ANC and gestational age at SP0, 
SP1, SP2 (relative to SP3) on newborn head circumfer-
ence. None were significant or of any added explanatory 
value. This suggests that the effects of SP dosage, gesta-
tional age, and ANC attendance on changes in newborn 
head circumference appeared to operate independently 
of each other.
The mean head circumference by month of birth in 
the counterfactual LGA, showed a surge in October in 
both the number of SP doses and head circumferences. 
This coincided with data quality audit visits, that likely 
increased community awareness of SP. October data 
were excluded and the unadjusted and adjusted analy-
ses were re-run. All estimates increased in magnitude, 
and with stronger statistical significance. There was also 
a stronger SP linear association between higher SP doses 
and increased head circumference, as well as a stronger 
intervention effect. Therefore, there may have been a 
“community mobilization” effect of data quality audits 
carried out in the counterfactual group. See Additional 
files 4 and 5.
Findings relating to stillbirths
There were 213 stillbirths out of 9453 births that 
occurred after 7  months of gestation, equivalent to an 
overall stillbirth rate (SBR) of 23 per 1000 births. The 
SBR by dose of SP was calculated, and unexpectedly 
showed that women who ingested zero doses (SBR = 21 
per 1000 term births) had a lower SBR than those who 
had ingested SP1 (SBR  =  37 per 1000 term births) or 
SP2 (SBR = 22 per 1000 term births). (Table 10) Among 
women who ingested at least one dose of SP, a strong cor-
relation between increasing SP doses and declines in SBR 







April May June July August September October November
 Intervenon LGAs Counterfactual LGA
Fig. 9 Mean head circumference in the intervention and counterfactual LGAs by birth month (April–November 2015)
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Table 11 presents the unadjusted odds of women hav-
ing a stillbirth between April and November. The odds 
of having a stillbirth were higher among women who 
ingested less than three doses of SP, but was only statisti-
cally significant when contrasted to SP1 (OR 2.04). Being 
resident in the intervention LGA versus the counter-
factual LGA was not a significant predictor of a woman 
having a stillbirth. Newborns that were delivered later 
in the study were no different from those born ear-
lier in the odds of being a stillbirth. Any ANC attend-
ance significantly reduced the odds of a woman having 
a stillbirth (OR 0.57). Primigravid women (OR 1.87) and 
those mothers who gave birth in a facility (OR 1.86) had 
significantly higher odds of a stillbirth compared to mul-
tigravida women and those who gave birth at home.
Table  12 shows the adjusted odds of a woman having 
a stillbirth. Fewer doses of SP taken was associated with 
higher odds of stillbirth; only the difference between 
the first dose and three doses was significant at p < 0.05. 
(adj. OR 1.77). As in the univariate results, there was no 
significant association between residing in the interven-
tion (vs. counterfactual) sites and the odds of stillbirth, 
nor with giving birth later on in the course of the study. 
Adjusting for all of the other variables in the model, any 
ANC attendance was associated with a statistically sig-
nificant 66% decline in the odds of a woman having a 
stillbirth (adj. OR 0.44). Definitively, primigravida women 
(adj. OR 1.81) had higher odds of a stillbirth, relative to 
multigravida women. Women that gave birth in a facility 
(adj. OR 1.99) were significantly more likely to have had 
a stillbirth, relative to those who did not give birth in a 
facility.
As with head circumference, ANC attendance and 
higher SP dosages were significantly associated with the 
odds of stillbirth. None of the tests for any interaction 
between ANC attendance and SP dosages were either 
significant or added importance to the model fit. As with 
head circumference findings, the impact of higher SP 
dosages and ANC attendance with the odds of stillbirth 
appeared to operate independently.
Findings relating to costing
Cost per woman
Given the total number of women reached in this study 
with SP, the average cost per woman who received SP1-3 
ranged from N1,132 ($5.7) to N1,518 ($7.6) in the three 
intervention LGA to N5,326 ($26.7) in the counterfac-
tual LGA (see Table 13). Given that majority of the costs 
associated with the delivery of SP doses per woman were 
fixed costs and are, therefore, comparable across LGAs 
in the intervention and counterfactual alike, the spread 
in cost per woman reached with SP1-3 in intervention 
LGAs is explained primarily by differences in the actual 
number of women that got all three doses of SP. A higher 
number of women who got all three doses is a function of 
reaching the most women with SP1 in the first instance 
and subsequently ensuring that there were few dropouts 
in women who received SP2 and SP3. The higher cost per 
woman in the counterfactual LGA reflects the overall low 
number of women on SPI, the higher dropout by SP2 and 
the absence of women reached with SP3. The 3.5- to 4.6-
fold lower average costs per woman in the intervention 
LGA suggests that strategies that substantially increase 
coverage and significantly reduce drop out in-between 
doses, will lower the average cost per woman.
Table 8 Unadjusted mean head circumference (HC) in mil-
limeters (mm) among  live newborns born between  April 
and November 2015, and differences in mean HC by avail-
able variables
n Mean HC in mm SD Pr > |t|
Sex of infant
 Female 3235 353.90 22.17 <0.001
 Male (ref ) 3477 356.30 22.76
Intervention
 Yes 4583 356.20 23.88 <0.001
 No (ref ) 2137 352.70 19.07
SP dosage
 0 2258 353.63 23.51 <0.0001
 1 871 355.39 23.14 0.10
 2 1682 354.90 21.37 0.01
 3+ (ref ) 1909 356.93 21.89
Primigravida
 Yes 1225 354.30 22.57 0.18
 No (ref ) 5486 355.30 22.51
At least 1 ANC visit
 Yes 3805 356.00 20.19 0.00
 No (ref ) 2915 354.00 25.20
Month of birth
 April 755 360.50 22.89 <0.0001
 May 887 355.49 20.92 0.54
 June 838 353.06 20.86 0.11
 July 766 354.53 23.78 0.79
 August 809 354.31 22.61 0.64
 September 860 352.98 26.17 0.09
 October 959 355.63 20.88 0.45
 November (ref ) 846 354.83 21.14
Gestational age at delivery (months)
 8 18 342.50 26.44 0.00
 9 6588 355.06 22.57 0.01
 10 (ref ) 113 360.26 17.29
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Cost per SP dose
The estimated cost per course per dose of SP1, SP2 and 
SP3 ranged from NGN 185 ($0.9) to NGN288 ($1.45) 
in the intervention LGAs compared to a much higher 
cost of NGN 1382 ($6.98) in the counterfactual LGA. 
The estimated cost per course per dose of SP1, SP2, SP3 
and SP4+ ranged from NGN 239 ($1.21) to NGN373 
($1.89) in the intervention LGAs, compared to NGN 
1843 ($9.21) in the counterfactual LGA (see Table  14). 
The observed substantial difference in the cost of a SP1-3 
regimen in the counterfactual LGA is attributable to no 
reportable distribution activity with SP3 and higher. The 
incremental cost per dose of SP1, SP2, SP3 and SP4+ 
on SP1, SP2, SP3 and ranged from NGN 53.5 ($0.27) to 
NGN85 ($0.43) in the intervention LGAs compared to a 
)fer(+3210
SP dosage 39.65309.45393.55336.353









Fig. 10 Mean newborn head circumference in mm by number of SP doses during pregnancy, for births between April and November 2015
Table 9 Adjusted associations between  selected vari-
ables and the mean head circumference (HC) of newborns, 
between April and November 2015
n = 6702; F test p < 0.0001; Adj. r-square 0.017; RMSE: 22.6
Estimate Standard error Pr > |t|
Intercept 363.78 2.77 <0.0001
Sex of infant
 Female −2.33 0.55 <0.0001
 Male (ref )
Intervention
 Yes 2.88 0.66 <0.0001
 No (ref )
SP dosage
 0 −2.87 0.87 0.00
 1 −1.88 0.93 0.04
 2 −2.55 0.78 0.00
 3+ (ref )
Primigravida
 Yes −1.16 0.71 0.10
 No (ref )
At least 1 ANC visit
 Yes 2.01 0.62 0.00
 No (ref )
 Month of birth −0.64 0.13 <0.0001
Gestational age at delivery (months)
 8 −17.83 5.68 0.00
 9 −3.73 2.14 0.08
 10 (ref )
Table 10 Frequency of  Stillbirths by  number of  SP doses, 
and  Stillbirth rate (SBR) between  April and  November 
2015
A stillbirth was defined as an infant born at 8 months or more gestational age, 
who showed no signs of life at birth
SBR the number of stillbirths per thousand births
Status at birth Number of SP doses
0 1 2 3+ Total
Livebirth 2644 1142 2233 3221 9240
Stillbirth 57 44 51 61 213
Total births 2701 1186 2284 3282 9453
SBR 21 37 22 19 23















Fig. 11 Stillbirth rate by 1, 2 and 3+ doses of SP, for births between April and November 2015
Table 11 Unadjusted odds of having a stillbirth (vs. a live 
birth) between  April and  November 2015 in  four LGA’s 
in Sokoto State
9453 births that occurred >28 weeks gestation
a n = 9438
b, * Significant at p < 0.05
Parameter OR 95% CIb
SP dosage
 0 1.14 0.79 1.64
 1 2.04* 1.37 3.02
 2 1.21 0.83 1.76
 3+ (ref )
Intervention
 Yes 1.10 0.79 1.53
 No (ref )
At least 1 ANC visit
 Yes 0.57* 0.43 0.75
 No (ref )
Primigravidaa
 Yes 1.87* 1.38 2.53
 No (ref )
Place of birth
 Facility 1.86* 1.23 2.80
 Home (ref )
Month of birth
 July–November 0.85 0.64 1.13
 April–June (ref )
Table 12 Adjusted odds of  having a stillbirth (vs. a live 
birth) between  April and  November 2015 in  four LGA’s 
in Sokoto State
*n = 9438; L-R p value < 0.001; c-statistic = 0.65; Hosmer and Lemeshow 
Goodness-of-Fit pr Chi-sq >0.3753 test
Parameter OR 95% CI
SP dosage
 0 0.76 0.49 1.18
 1 1.77 1.18 2.66
 2 1.18 0.80 1.74
 3+ (ref )
Intervention
 Yes 0.90 0.62 1.30
 No (ref )
At least 1 ANC visit
 Yes 0.44 0.32 0.61
 No (ref )
Primigravida
 Yes 1.81 1.33 2.47
 No (ref )
Place of birth
 Facility 1.99 1.28 3.10
 Home (ref )
Month of birth
 July–November 0.81 0.60 1.11
 April–June (ref )
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much higher NGN 460.87 ($2.33) in the counterfactual. 
The observed five- to eightfold higher cost per SP dose in 
the counterfactual LGA is the cost of underperformance 
of not being at programme scale.
Discussion
To the best of our knowledge, this is the first published 
implementation research study that has prospectively 
examined the association between SP use and newborn 
outcomes, at scale, in community settings. This study is 
the largest cohort of pregnant women included in a study 
designed and powered to examine the effects of IPTp-SP 
delivered at scale.
Study data show that IPTp-SP can be delivered safely 
to pregnant mothers, in accordance with Nigeria’s Fed-
eral Ministry of Health and applicable WHO guidelines. 
The results have also shown that community-based dis-
tribution of SP, twinned with facility-based distribution, 
produced a superior and sustained coverage in the use 
of SP by pregnant women, at scale. In this context, com-
munity-based distribution of SP substantially increased 
facility-based distribution of SP. Critical attention given 
to realizing authentic community ownership, through 
upfront education and an early community discern-
ment of SP’s beneficial results, contributed to a dramatic 
increase in the consumption of SP.
The MiPP project did not directly or indirectly inter-
vene on the availability of water to ingest medicines in 
facilities, although this is a factor that has been cited as a 
contributor to low IPTp-SP coverage [36–38]. The surge 
of IPTp-SP use in facilities in the intervention LGAs sug-
gests that increasing demand for IPTP-SP would intrin-
sically motivate to overcome barriers to accessing water 
to ingest her medicine. Additionally, in the interven-
tion LGA’s, IPTp-SP was recorded only after it had been 
observed ingested, by the CBV.
Any antenatal care attendance was strongly predictive 
of larger newborn head circumference and a reduced 
odds of stillbirths. The authors call for urgent action by 
policy makers and programmes to increase communi-
ties’ access to and utilization of quality ANC services in 
Sokoto State and Nigeria. This finding affirms the Global 
Malaria in Pregnancy Working Group’s call that any 
efforts intended to increase IPTp-SP delivery at scale, 
need to also increase ANC usage. The study reinforced, 
but was not conclusive about, the increased susceptibil-
ity of primigravid mothers to having stillbirths. There 
is already well-established local, tacit knowledge in 
Sokoto State communities that primigravid mothers suf-
fer greater risks in pregnancy, and therefore need more 
care. It is recommended that advocacy and community 
education efforts capitalize on this notion to increase 
greater use of ANC and health facility delivery services 
by primigravid women. The study also confirmed a well-
established finding that male newborns had larger head 
circumferences than female ones, and lends biological 
validity the study findings as a whole.
The finding that women who gave birth in a health 
facility compared to home deliveries had higher odds of 
having stillborn babies was puzzling at first glance. How-
ever, in a setting like Sokoto State where home delivery is 
regretfully almost universal, women with complications 
are more likely to be referred to primary health facili-
ties, and consequently with their newborns suffer higher 
case fatalities than home births. The implication is that 
primary health facilities operate as de facto second-
ary level care facilities, without requisite support. More 
needs to be done to increase health centres’ preparedness 
to deliver basic emergency obstetric care. Policy actions 
that remove barriers to women’s access health facilities 
for deliveries in Sokoto State and Nigeria are urgently 
warranted.
Table 13 Cost per woman who received SP 1-6 contrasted by intervention and counterfactual LGAs
LGAs
Goronyo [Cost per woman 
in 2015 Nigerian Naira 
(NGN)]
Silame [Cost per woman 
in 2015 Nigerian Naira 
(NGN)]
Dange Shuni [Cost 
per woman in 2015 Nige‑
rian Naira (NGN)]
Yabo [Cost per woman 
in 2015 Nigerian Naira 
(NGN)]
SP dose level
 Women who received SP1 723 1228 947 4155
 Women who received SP2 963 1575 1235 6498
 Women who received SP3 1710 2857 2371
 Women who received 
SP4+ (SP5, SP6)
4889 9269 12,169
 Average cost per woman 
SP1–SP3
1132 1887 1518 5326
 Average cost per woman 
SP1–SP4+
2071 3732 4180 5326
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Given these findings on the benefits of SP3 doses and 
higher on newborn survival, the pathway to realize popu-
lation level benefits rests with getting IPTp-SP interven-
tions implemented at scale. The evidence suggests that a 
community distribution stratagem, that is well designed 
to increase coverage, and also amplifies the use of facil-
ity-based services, is both feasible and indispensable 
in Sokoto State and Nigeria. This programme used a 
health systems approach combined with human-centered 
design to build on the Nigeria National Primary Health 
Care Development Agency’s “minimum health care pack-
age guidelines”. Lessons from this programme can be 
used by state governments who would like to accelerate 
at scale implementation of primary health care service.
SP was readily integrated to other ongoing MNCH 
activities including the provision of chlorhexidine gel 
for care of the newborn cord and misoprostol to prevent 
postpartum haemorrhage. It is also instructive that there 
were effectively no incidents of stock out of SP of note 
during the study; this was instrumental to the results. It 
was helpful that a community health information sys-
tem, derived from household databases aided the pro-
active identification of women who received reminders. 
It enabled timeliness and greater precision in reaching 
women with SP services. Presently, the Federal Ministry 
of Health’s web-based health information system, DHIS2 
does not collect SP3 or higher doses at all. The DHIS2 
should be revised to capture at least three doses of SP, 
and higher, in line with current national and WHO SP 
policy guidelines.
Another factor that may have facilitated the scale up 
of IPTp-SP delivery, was the power of social diffusion. 
Women who had received SP gave public testimony that 
they felt their babies at birth, were larger than in previous 
births; they made uncharacteristic, prideful public dis-
plays of their babies. Mothers also gave personal testimo-
nies to their peers that SP made them feel healthier while 
being pregnant. This phenomenon may have helped to 
increase the proportion of women who declared their 
pregnancy earlier, started SP use earlier, and received 
higher mean doses of SP. It should be emphasized that 
mothers and communities want to experience tangible 
results, as an incentive to lend critical support to scaled-
up health interventions. With acceptance of the promise 
of results, communities, as a measure of their trust, used 
their own funds to recruit additional volunteers to cover 
hard-to-reach areas. They were also very proactive in the 
use of information from monthly review meetings to sus-
tain programme momentum.
Inclusive of the cost of SP, it cost between US$0.93 and 
$1.20 per three doses in the intervention LGAs. These 
lower cost ratios were the result of increased demand 
for SP, enabled by community-based distribution plus 
and facility distribution, as well as the reduced number 
missed opportunities in clinics. The higher equivalent 
cost of $6.9 per three doses in the counterfactual LGA, 
reflects the higher cost associated with a facility-only 
stratagem of distribution and the ensuing low demand 
for SP. A scale-up of IPTp-SP that utilizes both commu-
nity and facility based service delivery, will reduce the 
cost per woman served and cost per dose given; it is, 
therefore, recommended in Sokoto State and in Nigeria.
The finding of a decline in the mean newborn head 
circumference in births month on month from April 
to November in both intervention and counterfactual 
groups, suggest factors other than placental malaria at 
play in worsening newborn outcomes. One likely factor, 
beyond the scope of this study, is the role of maternal 
nutrition on newborn outcomes. Mothers whose babies 
were born in April had more access to post harvest foods 
for at least 5 months. A combination of better maternal 
nutrition and better protection from placental malaria is 
likely to increase the odds of newborn survival. The inter-
play of maternal nutrition and placental malaria is an 
area of further study.
Limitations
The data collection instrument in this study was designed 
to collect a handful of simple metrics that could evalu-
ate the impact of community based IPTp-SP in a context 
of low literacy. Data collected by CBHV supervisors did 
not capture many of the socioeconomic, nutritional and 
behavioral issues that affect newborn outcomes.
The WHO defines a stillbirth as a pregnancy as “a baby 
born with no signs of life at or after 28 weeks’ gestation” 
[39]. The definition of stillbirth used in this study was a 
crude, yet pragmatic, measure in the community pro-
gramme context of Sokoto State. While this does present 
a potential for misclassification of stillbirths, the finding 
of biologically plausible associations between SP doses 
and a reduction in the odds of stillbirths, enhance the 
internal validity of the study.
Although every effort was undertaken to standardize 
head circumference measurements, it is probable that 
there were variations in where the tape measure was 
placed. Given the large sample size of newborns, errors 
in head circumference measurements would be normally 
distributed. Every effort was made to ensure head circum-
ference measurement as close to birth and no later than 
7  days postpartum. On this basis, as mentioned earlier, 
2521 newborns principally in the intervention group, that 
were 8 days or older before they could be measured were 
excluded. The overall validity of the study is strengthened 
by findings that confirm an already established, biologi-
cally plausible, association between gestational age and 
the sex of the newborn on newborn head circumference.
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The intervention deployed, although primarily the 
introduction of SP at the community and the training of 
facility-based health workers to reduce missed opportu-
nities, it also included the restoration of linkages between 
communities and facilities, to promote referrals. The 
system for finding and enumerating women, which dou-
bled as community mobilization, and was confined to 
intervention LGAs, and not introduced into the coun-
terfactual LGA. To have introduced the house-to-house 
enumeration visits in the counterfactual LGA, would 
have increased community awareness and increased 
demand for SP, as was evident in the spike in SP use that 
occurred with the data collection on birth outcomes. 
In effect, the house-to-house enumeration served as a 
co-intervention. As seen in Table 4, the house-to-house 
enumeration, in two intervention areas, showed a higher 
number of eligible women than were estimated from offi-
cial population estimates. This suggests that, if anything, 
there is most probably have an under estimate of the 
number of eligible women in the counterfactual area. If 
this was the case, coverage rates of IPTp-SP in the coun-
terfactual LGA would be even lower than estimated.
Conclusion
The study findings underscore the untapped potential of 
results-driven primary health care programming inclu-
sive of trained community health workers, to accelerate 
and safely implement IPTp-SP delivery at scale. The scale 
up of IPTp-SP programmes, that include a vital commu-
nity distribution component, is an important stratagem 
for inclusion in national policy strategies. An optimally 
scaled-up IPTp-SP programme is more likely to reach 
the underserved, also the most likely to suffer inequi-
ties. Consideration should be given to systems thinking 
enabled human-centered design principles to help match 
scale up objectives with strategies most likely to yield 
local trust, ownership and predictable availability of qual-
ity services.
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